Pharmaceutical

CD70 CAR-T by UTC Therapeutics for Burkitt Lymphoma: Likelihood of Approval

CD70 CAR-T is under clinical development by UTC Therapeutics and is currently in the Phase II in clinical pathway.

Aug 10, 2023 - 20:00
CD70 CAR-T is under clinical development by UTC Therapeutics and is currently in the Phase II in clinical pathway.
Read the original article

Tags:

Previous Article

CD70 CAR-T by UTC Therapeutics for Follicular Lymphoma: Likelihood of Approval

Next Article

CD70 CAR-T by UTC Therapeutics for Mantle Cell Lymphoma: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Dana-Farber’s divorce from Brigham is the culmination of decades of change

STAT+: Dana-Farber’s divorce from Brigham is the culmin...

Oct 16, 2023

FDA approves Alvotech and Teva’s SELARSDI for new indications

FDA approves Alvotech and Teva’s SELARSDI for new indic...

Oct 24, 2024

FDA advisory panel backs Pfizer’s RSV vaccine, but expresses some safety concerns

FDA advisory panel backs Pfizer’s RSV vaccine, but expr...

May 19, 2023